IFNG and neoplasm: Thus, CAR T-vax therapy amplifies CAR T-cell-derived IFN-γ that is critical for initial tumor control and antigen spreading, but also requires host-derived IFN-γ at later time points in the treatment, consistent with the important role for endogenous T cells in preventing tumor relapse.